Helen Hobbs

Helen Hobbs is a professor at the University of Texas Southwestern Medical Center, and a Howard Hughes Medical Institute investigator, who won a 2016 Breakthrough Prize in Life Sciences and the 2015 Pearl Meister Greengard Prize. She helped find that people with hypomorphic PCSK9 mutations had lower LDL levels, and were almost immune to heart disease. This discovery helped lead to cholesterol-lowering drugs that mimicked the effects of the PCSK9 mutations.^[1] She sits on the board of directors at Pfizer.

References